Remove 2029 Remove Pharmaceuticals Remove Vaccine
article thumbnail

Fewer New Drugs but Affordable Access for Existing Ones: The Big Elephant in the Room

Policy Prescription

Would you vote for legislation to lower drug prices that would lead to a five percent reduction in pharmaceutical innovation — yet simultaneously create a health system in which all Americans could afford the prescription drugs they need? He reminds us that the vaccines were developed with billions of taxpayer dollars.

Drugs 52
article thumbnail

What is the largest CRO in the US?

Vial

Introduction Contract research organizations (CROs) are essential in pharmaceutical research and development (R&D). billion by 2029. By geographical region, the global CRO services market in 2023 was dominated by North America. As a result, the global CRO market is estimated to grow at a compound annual growth rate (CAGR) of 9.6%

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

CMS Finalizes Guidance on Medicare Part D Manufacturer Discount Program

FDA Law Blog: Biosimilars

covered insulin product or vaccine). state pharmaceutical assistance programs). Each phase-in policy allows eligible manufacturers to build up in a stepwise manner to the 10% and 20% applicable discounts by 2029 and 2031, respectively. had Part D expenditures on or before August 16, 2022).

article thumbnail

Making a “Miracle” HIV Medicine

Codon

million new HIV infections by 2029, undermining progress toward the UN’s goal. In 2024, the pharmaceutical company Gilead announced that a single injection of lenacapavir protected 96 to 100 percent of recipients from HIV for up to six months. A lifelong HIV vaccine would be ideal, but developing one has proved difficult.